Costanzo Maria C, Akolkar Beena, Claussnitzer Melina, Florez Jose C, Gloyn Anna L, Grant Struan F A, Kaestner Klaus H, Manning Alisa K, Mohlke Karen L, Parker Stephen C J, Titchenell Paul M, Udler Miriam S, Jones Melissa A, Kamphaus Tania N, Fischer Rachel A, McCarthy Mark I, Miller Melissa R, Boehnke Michael, Flannick Jason, Burtt Noël P
Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Diabetes. 2025 Jul 1;74(7):1089-1098. doi: 10.2337/db25-0042.
UNLABELLED: In the last two decades, significant progress has been made toward understanding the genetic basis of type 2 diabetes. An important supporter of this research has been the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), most recently through the Accelerating Medicines Partnership Program for Type 2 Diabetes (AMP T2D) and Accelerating Medicines Partnership Program for Common Metabolic Diseases (AMP CMD). These public-private partnerships of the National Institutes of Health, multiple biopharmaceutical and life sciences companies, and nonprofit organizations, facilitated and managed by the Foundation for the National Institutes of Health, were designed to improve understanding of therapeutically relevant biological pathways for type 2 diabetes. On the occasion of NIDDK's 75th anniversary, we review the history of NIDDK support for these partnerships, which saw the convergence of research directions prioritized by academic consortia, the pharmaceutical industry, and government funders. Although the NIDDK was not the sole originator or funder of these efforts, its support and leadership have been pivotal to the partnerships' success and have enabled their research to be broadly accessible through the AMP Common Metabolic Diseases Knowledge Portal (CMDKP) and the AMP Common Metabolic Diseases Genome Atlas (CMDGA). Findings from AMP CMD align with NIDDK's mission to conduct research and share results with the goal of improving health and quality of life. ARTICLE HIGHLIGHTS: The Accelerating Medicines Partnership Program for Type 2 Diabetes (AMP T2D) and Accelerating Medicines Partnership Program for Common Metabolic Diseases (AMP CMD) were created to accelerate the translation of genetic and genomic data into knowledge about the biology of disease. Their goal was to gain a better understanding of the mechanisms underlying types 1 and 2 diabetes and prediabetes, obesity, cardiovascular disease, kidney disease, and nonalcoholic steatohepatitis. This work identified multiple genes and pathways underlying these diseases. The findings of AMP T2D and AMP CMD have implications for drug development and improved risk prediction, diagnosis, and treatment for common metabolic diseases.
未标注：在过去二十年中，在理解2型糖尿病的遗传基础方面取得了重大进展。这项研究的一个重要支持者是美国国立糖尿病、消化和肾脏疾病研究所（NIDDK），最近是通过2型糖尿病加速药物合作计划（AMP T2D）和常见代谢疾病加速药物合作计划（AMP CMD）。这些由美国国立卫生研究院、多家生物制药和生命科学公司以及非营利组织组成的公私合作项目，由美国国立卫生研究院基金会推动和管理，旨在增进对2型糖尿病治疗相关生物学途径的理解。在NIDDK成立75周年之际，我们回顾了NIDDK对这些合作项目的支持历史，这些项目见证了学术联盟、制药行业和政府资助者所优先考虑的研究方向的融合。尽管NIDDK并非这些努力的唯一发起者或资助者，但其支持和领导对合作项目的成功至关重要，并使他们的研究能够通过AMP常见代谢疾病知识门户（CMDKP）和AMP常见代谢疾病基因组图谱（CMDGA）广泛获取。AMP CMD的研究结果与NIDDK开展研究并分享成果以改善健康和生活质量的使命相一致。 文章亮点：2型糖尿病加速药物合作计划（AMP T2D）和常见代谢疾病加速药物合作计划（AMP CMD）的设立是为了加速将遗传和基因组数据转化为有关疾病生物学的知识。其目标是更好地理解1型和2型糖尿病、糖尿病前期、肥胖症、心血管疾病、肾脏疾病和非酒精性脂肪性肝炎的潜在机制。这项工作确定了这些疾病背后的多个基因和途径。AMP T2D和AMP CMD的研究结果对药物开发以及改善常见代谢疾病的风险预测、诊断和治疗具有重要意义。
JBI Database System Rev Implement Rep. 2016-4
Diabetes. 2025-7-1
Diabetes Care. 2025-7-1
Diabetes. 2025-7-1
Wellcome Open Res. 2023-10-20
Am J Hum Genet. 2024-9-5
Nat Med. 2024-4
Zotero 插件
